Partnership Brings First Mastercard-Approved TON Card Program Enabling Native Cryptocurrency Spending from Digital Wallets with ALT5 IntegrationNew York, NY, Nov. 03, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp ("AlphaTON Capital" or the "Company") (Nasdaq: ATON), a specialized digital asset treasury company focused on the Telegram ecosystem, today announced a strategic joint venture with PagoPay to develop and launch a crypto-enabled Mastercard payment card program that enables cardholders to natively s ...

Consulting-led projects with deep functional specialization have improved velocity, reliability, and operating leverage for mid-market and PE-backed companiesNEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aeries Technology, Inc. (NASDAQ: AERT), a global leader in AI-powered business transformation and Global Capability Center (GCC) services, today highlighted its expanded portfolio of AI-enabled implementation projects that complement its core GCC-building capabilities. Delivered through consulting-led executi ...

公司人事任命 - Vor Bio任命Jeremy Sokolove博士为首席医疗官[1] - 新任首席医疗官在风湿病学和自身免疫疾病研发领域拥有超过20年的临床和转化经验[1] 新任高管背景 - Jeremy Sokolove博士最近担任Roivant Sciences的首席医疗官，负责新型治疗机会的战略评估和授权引进[2] - 他曾担任Odyssey Therapeutics的首席医疗官，领导公司向临床阶段生物技术组织转型[2] - 他曾在GSK担任高级副总裁兼临床药理学和实验医学负责人，领导专业药物组合的早期和转化开发[2] - 他曾在艾伯维担任免疫学转化科学负责人，指导早期临床项目并建立组合范围内的转化医学策略[2] - 他的职业生涯始于斯坦福大学医学院，担任执业风湿病学家和主要研究员[2] 新任高管资质 - Jeremy Sokolove博士拥有广泛的内科和风湿病学执业经验，治疗患者并领导自身免疫和炎症性疾病临床研究项目[3] - 他在免疫学和风湿病学领域发表大量著作，为理解免疫介导的疾病机制做出贡献[3] - 他持有波士顿大学医学院的医学博士学位，并拥有内科和风湿病学的委员会认证[3] 公司战略与产品管线 - 公司专注于通过三期临床开发和潜在商业化快速推进telitacicept，这是一种新型双靶点融合蛋白[5] - Telitacicept旨在解决全球严重的自身抗体驱动性疾病[5] - 公司采用双BAFF/APRIL方法，旨在精确调节自身免疫疾病的核心机制[4] - Telitacicept代表了一个差异化的近期机会，有望显著改善治疗选择有限或依赖广泛免疫抑制的患者的预后[4]

Clinical evaluation of the product by design surgeons completed, driving early commercial momentum SALT LAKE CITY, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced ceramic biomedical applications of silicon nitride (Si₃N₄), today announced the execution of a private label agreement to supply OsseoSculpt™, a next-generation biologic designed to complement the Company’s FDA 510(K) cleared SINAPTIC® Foot & Ankle Osteotomy Wedge Sys ...

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching ‘The Other TD’ campaignTD is a chronic movement disorder impacting one in four people who take certain prescription mental health medications. While TD can impact your daily life, it can be treated without interrupting your mental health treatment1-4Younger individuals, men, and racial and ethnic minority groups have lower rates of formal diagnoses despite the high impact the movements often have on all aspects of ...

公司高层任命 - 任命Jeff Kerridge为全球销售高级副总裁，其拥有超过35年地理空间、国防与情报行业经验 [1] - Kerridge将领导公司的全球销售战略和客户增长计划，以加速其全球扩张 [1] 新任高管背景与业绩 - Kerridge是国防与情报及民用政府市场中备受尊敬的领导者 [2] - 其职业生涯中累计销售额超过20亿美元 [1] - 曾担任Maxar Intelligence国际销售高级副总裁兼总经理，带领团队在7年内创造超过10亿美元收入 [2] - 职业背景还包括在BlackSky、Aireon LLC的资深职位以及在中情局超过十年的任职经历 [3] 公司近期关键进展 - 完成由主要客户引领的3000万美元AI优先星座计划 [2] - 成功完成9000万美元的新资本融资，以加速星座部署和增长计划 [2][11] - 宣布下一代卫星星座，将提供增强的能力和分辨率 [2][11] - 成功完成公司迁册至美国，更好地与核心国防与情报客户群对齐 [2][11] - 新增重要合作伙伴，包括NASA、Uzma、Suhora和Vantor [2] 合作伙伴与客户拓展 - 被选入并加入NASA的商业小卫星数据采集计划，为科学和研究应用开辟新渠道 [11] - 确保重大国际协议，包括与中东Suhora的合同以及与马来西亚国家机构的合同 [11] - 通过其与Vantor的协议，扩展渠道合作伙伴关系，服务如国家地理空间情报局Luno计划等关键客户 [11] 公司商业模式与定位 - 公司是首家垂直整合的地理空间公司，致力于通过行星尺度的洞察带来真实成果 [5] - 其使命是通过高分辨率图像信息平台 democratize 获取地理空间数据，以帮助解决气候变化、能源供应和粮食安全等全球最紧迫问题 [6] - 公司正在构建一个可扩展、全自动的地球观测平台，目标是以最佳的重访频率和分辨率、前所未有的单位经济效益重新绘制整个地球地图 [5]

ANN ARBOR, Mich., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at the Jefferies Global Healthcare Conference – London on November 18, 2025, at 8:00 a.m. GMT (3:00 a.m. ET). The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Esperion Th ...

JACKSON CENTER, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB), through its collaboration with scientists at Mississippi State University, continues work on a planned fourth quarter submission to the United States government seeking contractual funding for advanced animal research for the development of an effective post-head-trauma treatment for Traumatic Brain Injury (TBI). The United States military, for example, has historically experienced rates of suicide among both active duty ...

Goal to have the bulk of equity for construction capital raised at the Brazil asset level, preserving the corporate capital structure while bringing in strategic partners MANAUS, Brazil, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Brazil Potash Corp. ("Brazil Potash" or the "Company") (NYSE American: GRO), a mineral exploration and development company with a critical mineral potash mining project, the Autazes Project (the "Project"), today announced it has appointed BTIG, LLC as its lead financial advisor to secure a ...

Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the third quarter 2025, after the market close on November 11, 2025. Following the release ...